KR102312817B1 - C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법 - Google Patents

C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법 Download PDF

Info

Publication number
KR102312817B1
KR102312817B1 KR1020167013463A KR20167013463A KR102312817B1 KR 102312817 B1 KR102312817 B1 KR 102312817B1 KR 1020167013463 A KR1020167013463 A KR 1020167013463A KR 20167013463 A KR20167013463 A KR 20167013463A KR 102312817 B1 KR102312817 B1 KR 102312817B1
Authority
KR
South Korea
Prior art keywords
inh
delete delete
pharmaceutical composition
patients
amr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167013463A
Other languages
English (en)
Korean (ko)
Other versions
KR20160079821A (ko
Inventor
콜린 브룸
마르크 이. 욱니스
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102312817(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Priority to KR1020217032180A priority Critical patent/KR102384814B1/ko
Publication of KR20160079821A publication Critical patent/KR20160079821A/ko
Application granted granted Critical
Publication of KR102312817B1 publication Critical patent/KR102312817B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020167013463A 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법 Active KR102312817B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217032180A KR102384814B1 (ko) 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US61/907,550 2013-11-22
US201462029086P 2014-07-25 2014-07-25
US62/029,086 2014-07-25
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217032180A Division KR102384814B1 (ko) 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법

Publications (2)

Publication Number Publication Date
KR20160079821A KR20160079821A (ko) 2016-07-06
KR102312817B1 true KR102312817B1 (ko) 2021-10-13

Family

ID=52016153

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167013463A Active KR102312817B1 (ko) 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법
KR1020217032180A Active KR102384814B1 (ko) 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217032180A Active KR102384814B1 (ko) 2013-11-22 2014-11-21 C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법

Country Status (24)

Country Link
US (3) US9895428B2 (https=)
EP (3) EP4162947A1 (https=)
JP (5) JP6431912B2 (https=)
KR (2) KR102312817B1 (https=)
CN (2) CN105744949A (https=)
AU (2) AU2014352846B2 (https=)
BR (1) BR112016011499A2 (https=)
CA (1) CA2930964A1 (https=)
CY (1) CY1121298T1 (https=)
DK (1) DK3071219T3 (https=)
ES (1) ES2708655T3 (https=)
HR (1) HRP20190184T1 (https=)
HU (1) HUE041809T2 (https=)
LT (1) LT3071219T (https=)
ME (1) ME03318B (https=)
MX (2) MX378834B (https=)
NZ (2) NZ719724A (https=)
PL (1) PL3071219T3 (https=)
PT (1) PT3071219T (https=)
RS (1) RS58343B1 (https=)
SG (1) SG10201804326SA (https=)
SI (1) SI3071219T1 (https=)
SM (1) SMT201900042T1 (https=)
WO (1) WO2015077543A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4162947A1 (en) 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
IL273185B2 (en) 2017-09-15 2024-10-01 Cedars Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210106521A (ko) * 2018-12-20 2021-08-30 세다르스-신나이 메디칼 센터 기관 이식체의 만성 항체 매개된 거부의 치료에서 클라자키주맙
EP4010010A4 (en) * 2019-08-08 2023-08-09 Cedars-Sinai Medical Center METHODS FOR IMPROVING ORGAN FUNCTION
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2022109124A1 (en) * 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
JP5722524B2 (ja) * 2006-03-02 2015-05-20 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体活性を抑制することによる同種移植片の生存の延長
KR101956585B1 (ko) * 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
CN105188750A (zh) * 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov Archive (2013.11.18.), URL:https://ciinicaltrials.gov/archive/NCT01147302/2013_11_18*
J Immunol, Vol. 190, pp. 3839-3847 (2013.04.15.)*

Also Published As

Publication number Publication date
AU2020200015A1 (en) 2020-01-30
EP3071219A1 (en) 2016-09-28
US20150147319A1 (en) 2015-05-28
ME03318B (me) 2019-10-20
KR102384814B1 (ko) 2022-04-08
CA2930964A1 (en) 2015-05-28
DK3071219T3 (en) 2019-02-25
MX2021000332A (es) 2021-04-13
ES2708655T3 (es) 2019-04-10
CN105744949A (zh) 2016-07-06
KR20210125118A (ko) 2021-10-15
WO2015077543A1 (en) 2015-05-28
MX378834B (es) 2025-03-11
EP3494988B1 (en) 2022-08-03
NZ759187A (en) 2022-08-26
PT3071219T (pt) 2019-02-06
BR112016011499A2 (pt) 2020-10-27
JP2022179637A (ja) 2022-12-02
JP2016537380A (ja) 2016-12-01
JP2019023233A (ja) 2019-02-14
EP3494988A1 (en) 2019-06-12
LT3071219T (lt) 2019-01-10
AU2020200015B2 (en) 2022-03-10
US20180104319A1 (en) 2018-04-19
KR20160079821A (ko) 2016-07-06
US9895428B2 (en) 2018-02-20
HUE041809T2 (hu) 2019-05-28
AU2014352846A1 (en) 2016-06-02
NZ719724A (en) 2022-08-26
EP3071219B1 (en) 2018-11-14
JP2021063141A (ja) 2021-04-22
PL3071219T3 (pl) 2019-04-30
SI3071219T1 (sl) 2019-03-29
SMT201900042T1 (it) 2019-02-28
US20200360495A1 (en) 2020-11-19
HRP20190184T1 (hr) 2019-03-22
JP2019001831A (ja) 2019-01-10
CN111388655A (zh) 2020-07-10
JP6620206B2 (ja) 2019-12-11
RS58343B1 (sr) 2019-03-29
JP6431912B2 (ja) 2018-11-28
SG10201804326SA (en) 2018-06-28
AU2014352846B2 (en) 2019-10-03
CY1121298T1 (el) 2020-05-29
MX2016006656A (es) 2016-09-06
EP4162947A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
KR102312817B1 (ko) C1-에스테라제 억제제를 사용한 장기 이식 환자에서의 항체-매개성 거부반응의 치료 방법
EP1988882B1 (en) Prolongation of survival of an allograft by inhibiting complement activity
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
HK40091830A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK40008415B (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK40008415A (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241B (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1120444B (en) Prolongation of survival of an allograft by inhibiting complement activity

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000